Dedicated to improving care
Clinical Research
Elevating Urology Through Clinical Research
Conducting clinical research keeps us at the forefront of urology treatment and gives our patients access to promising treatments and expert knowledge. This research enables us to offer our patients in Philadelphia and surrounding counties the latest advancements in treatments.
Each clinical research trial follows strict guidelines to protect participants. Ask your doctor if there’s a trial that is right for you. Or call our Clinical Research Department at 610-667-0458.
Sponsors and CROs: Learn more about partnering with MidLantic Urology for your next urology trial.
Clinical Trials at MidLantic Urology
Clinical research trials play an essential role in bringing new treatments to our patients. Those who participate in trials enjoy the reassurance and security they get from being closely monitored, and the satisfaction that they are playing an important role in advancing medicine.
These clinical trials are currently available at MidLantic Urology.
Bladder Cancer
ABLE 22
NCT06545955
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Learn MoreABLE 32
NCT06510374
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Learn MoreCORE-008
NCT06567743
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Learn MoreJanssen Moonrise-1
NCT06319820
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Learn MoreJanssen Sunrise-5
NCT06211764
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (SunRISe-5)
Learn MoreJHU J18158
NCT03914794
Phase 2 Window of Opportunity Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients with Recurrent Low- or Intermediate-Risk Tumors
Learn MoreMerck 057
NCT02625961
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer
Learn MoreMoonrise 1
NCT06319820
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1)
Learn MorePivot-006
NCT06111235
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by observation for the treatment of participants with IR-NMIBC.
Learn MoreQUILT-2.005
NCT02138734
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Learn MoreProstate Cancer
AZ EvoPAR
NCT06120491
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
Learn MoreDendreon Boost
NCT06134232
An Open-Label, Multicenter Study of Subjects With Metastatic Castrate-Resistant Prostate Cancer Treated With PROVENGE® and Boosted With A Single Infusion of Sipuleucel-T to Measure Immune Response
Learn MoreHYDROSPACE
NCT06451614
HYDROSPACE study is a prospective, randomized, multicenter study to evaluate the safety and effectiveness of SpaceIT in patients undergoing External Beam Radiotherapy (EBRT) for the treatment of prostate cancer.
Learn MoreLantheus
NCT05712473
An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer
Learn MoreMK-004
NCT06136650
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)
Learn MoreMSK: DOCETAXEL & RADIUM -223 (DORA STUDY)
NCT03574571
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer.
Learn MorePROPELLA THERAPEUTICS
NCT04729114
Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
Learn MoreFor more information or to enroll in one of these trials, call MidLantic’s Clinical Research Department at 610-667-0458.
A Trusted Team
Clinical trials help scientists better understand disease and develop new medications, treatments, and devices. Our clinical research team is comprised of top physicians and specialists experienced in clinical research. We provide our patients with the opportunity to participate in clinical trials and gain access to the latest therapy and technology available to treat their urologic condition.
Led by Dr. Laurence Belkoff, D.O., F.A.C.O.S and Clinical Research Director Cheryl Zinar, RN, BSN, together oversee a dedicated research team of RNs, Research Assistants and Regulatory Specialists. Backed by a research committee of eight board certified physicians, we continually strive to advance urology health.
